3. Bibliografía

–Fernandez AP. Connective Tissue Disease: Current Concepts. Dermatol Clin. 2019; 37:37-48.

-Hughes M, Herrick AL. Raynaud’s phenomenon. Best Pract Res Clin Rheumatol. 2016; 30:112-32.

-Bernardino V, Rodrigues A, Lladó A, Panarra A. Nailfold capillaroscopy and autoimmune connective tissue diseases in patients from a Portuguese nailfold capillaroscopy clinic. Rheumatol Int. 2019. doi: 10.1007/s00296-019-04427-0.

–Weiss JE. Pediatric systemic lupus erythematosus: more than a positive antinuclear antibody. Pediatr Rev. 2012; 33:62-73.

-Shaikh MF, Jordan N, D’Cruz DP. Systemic lupus erythematosus. Clin Med (Lond). 2017; 17:78-83.

–Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, Bruce IN, Isenberg D, Wallace DJ, Nived O, Sturfelt G, Ramsey-Goldman R, Bae SC, Hanly JG, Sánchez-Guerrero J, Clarke A, Aranow C, Manzi S, Urowitz M, Gladman D, Kalunian K, Costner M, Werth VP, Zoma A, Bernatsky S, Ruiz-Irastorza G, Khamashta MA, Jacobsen S, Buyon JP, Maddison P, Dooley MA, van Vollenhoven RF, Ginzler E, Stoll T, Peschken C, Jorizzo JL, Callen JP, Lim SS, Fessler BJ, Inanc M, Kamen DL, Rahman A, Steinsson K, Franks AG Jr, Sigler L, Hameed S, Fang H, Pham N, Brey R, Weisman MH, McGwin G Jr, Magder LS. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012; 64:2677-86.

-Lowe CD, Brahe CA, Green B, Lam TK, Meyerle JH. Bullous systemic lupus erythematosus successfully treated with rituximab. Cutis. 2019; 103:E5-E7.

-Chanprapaph K, Sawatwarakul S, Vachiramon V. A 12-year retrospective review of bullous systemic lupus erythematosus in cutaneous and systemic lupus erythematosus patients. Lupus. 2017; 26:1278-1284.

-Akintayo RO, Olarinoye GM, Akintayo FC, Ilesanmi ON. Rowell Syndrome in Nigeria: Systemic Lupus Erythematosus Presenting as Recurrent Erythema Multiforme in a Young Woman. Acta Dermatovenerol Croat. 2019; 27:200-201.

-Pozharashka J, Dourmishev L, Balabanova M, Vassileva S, Miteva L. Rowell’s Syndrome Triggered by Omeprazole. Acta Dermatovenerol Croat. 2019; 27:124-126.

-Santiago L, Mascarenhas R, Tellechea Ó, Gonçalo M. Toxic epidermal necrolysis-like subacute cutaneous lupus erythematosus associated with lung carcinoma. BMJ Case Rep. 2019; 12. pii: e231152.

Ribero S, Sciascia S, Borradori L, Lipsker D. The Cutaneous Spectrum of Lupus Erythematosus. Clin Rev Allergy Immunol. 2017; 53:291-305.

-Kuhn A, Landmann A. The classification and diagnosis of cutaneous lupus erythematosus. J Autoimmun. 2014; 48-49:14-9.

-Wenzel J. Cutaneous lupus erythematosus: new insights into pathogenesis and therapeutic strategies. Nat Rev Rheumatol. 2019; 15:519-532.

-Günther C. Nucleic Acid Immunity in the Pathogenesis of Cutaneous Lupus Erythematosus. Front Immunol. 2019; 10:1636.

–Filotico R, Mastrandrea V. Cutaneous lupus erythematosus: clinico-pathologic correlation. G Ital Dermatol Venereol. 2018; 153:216-229.

-González-Cruz C, Aparicio Español G, Ferrer Fàbrega B, Cabezas Calderón V, Giner Pichel M, García-Patos Briones V. Lupus panniculitis: Clinicopathological features of a series of 12 patients. Med Clin (Barc). 2018; 151:444-449.

-Okon LG, Werth VP. Cutaneous lupus erythematosus: diagnosis and treatment. Best Pract Res Clin Rheumatol. 2013; 27:391-404.

-Alniemi DT, Gutierrez A Jr, Drage LA, Wetter DA. Subacute Cutaneous Lupus Erythematosus: Clinical Characteristics, Disease Associations, Treatments, and Outcomes in a Series of 90 Patients at Mayo Clinic, 1996-2011. Mayo Clin Proc. 2017; 92:406-414.

-Zhou W, Wu H, Zhao M, Lu Q. New insights into the progression from cutaneous lupus to systemic lupus erythematosus. Expert Rev Clin Immunol. 2020; 16:829-837.

–Callen JP. Cutaneous lupus erythematosus: Reflecting on practice-changing observations over the past 50 years. Clin Dermatol. 2018; 36:442-449.

-Rodriguez-Caruncho C, Bielsa I, Fernández-Figueras MT, Roca J, Carrascosa JM, Ferrándiz C. Lupus erythematosus tumidus: a clinical and histological study of 25 cases. Lupus. 2015; 24:751-5.

–Chen X, Wang S, Li L. A case report of lupus erythematosus tumidus converted from discoid lupus erythematosus. Medicine (Baltimore). 2018; 97:e0375.

–Rodsaward P, Chottawornsak N, Suwanchote S, Rachayon M, Deekajorndech T, Wright HL, Edwards SW, Beresford MW, Rerknimitr P, Chiewchengchol D. The clinical significance of antinuclear antibodies and specific autoantibodies in juvenile and adult systemic lupus erythematosus patients. Asian Pac J Allergy Immunol. 2019. doi: 10.12932/AP-211218-0465.

–Laurinaviciene R, Sandholdt LH, Bygum A. Drug-induced cutaneous lupus erythematosus: 88 new cases. Eur J Dermatol. 2017; 27:28-33.

-Timlin H, Wu M, Crespo-Bosque M, Geetha D, Ingolia A, Haque U, Towns MC, Grader-Beck T. Clinical Characteristics of Hydralazine-induced Lupus. Cureus. 2019; 11:e4996.

–Rosen JD, Paul S, Maderal A. A review of the evidence and cost of therapies for cutaneous lupus erythematosus. Lupus. 2019; 28:799-805.

-Company-Quiroga J, Alique-García S, Romero-Maté A. Current Insights Into The Management Of Discoid Lupus Erythematosus. Clin Cosmet Investig Dermatol. 2019; 12:721-732.

-Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, Cervera R, Doria A, Gordon C, Govoni M, Houssiau F, Jayne D, Kouloumas M, Kuhn A, Larsen JL, Lerstrøm K, Moroni G, Mosca M, Schneider M, Smolen JS, Svenungsson E, Tesar V, Tincani A, Troldborg A, van Vollenhoven R, Wenzel J, Bertsias G, Boumpas DT. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019; 78:736-745.

-Chew CY, Mar A, Nikpour M, Saracino AM. Hydroxychloroquine in dermatology: New perspectives on an old drug. Australas J Dermatol. 2019. doi: 10.1111/ajd.13168.

-Kuhn A, Landmann A, Wenzel J. Advances in the treatment of cutaneous lupus erythematosus. Lupus. 2016; 25:830-7.

-Wenzel J. Cutaneous lupus erythematosus: new insights into pathogenesis and therapeutic strategies. Nat Rev Rheumatol. 2019; 15:519-532.

-Fairley JL, Oon S, Saracino AM, Nikpour M. Management of cutaneous manifestations of lupus erythematosus: A systematic review. Semin Arthritis Rheum. 2019. pii: S0049-0172(19)30373-7.

-Damoiseaux J, Vulsteke JB, Tseng CW, Platteel ACM, Piette Y, Shovman O, Bonroy C, Hamann D, De Langhe E, Musset L, Chen YH, Shoenfeld Y, Allenbach Y, Bossuyt X. Autoantibodies in idiopathic inflammatory myopathies: Clinical associations and laboratory evaluation by mono- and multispecific immunoassays. Autoimmun Rev. 2019; 18:293-305.

-Sunderkötter C, Nast A, Worm M, Dengler R, Dörner T, Ganter H, Hohlfeld R, Melms A, Melzer N, Rösler K, Schmidt J, Sinnreich M, Walter MC, Wanschitz J, Wiendl H. Guidelines on dermatomyositis–excerpt from the interdisciplinary S2k guidelines on myositis syndromes by the German Society of Neurology. J Dtsch Dermatol Ges. 2016; 14:321-38.

-Mahil S, Marks D, McCormack M, Rahman A. Dermatomyositis. Br J Hosp Med (Lond). 2012; 73:C18-22.

-Volc-Platzer B. Dermatomyositis update. Hautarzt. 2015; 66:604-10.

-Bailey EE, Fiorentino DF. Amyopathic dermatomyositis: definitions, diagnosis, and management. Curr Rheumatol Rep. 2014; 16:465.

-Udkoff J, Cohen PR. Amyopathic Dermatomyositis: A Concise Review of Clinical Manifestations and Associated Malignancies. Am J Clin Dermatol. 2016; 17:509-518.

-Long K, Danoff SK. Interstitial Lung Disease in Polymyositis and Dermatomyositis. Clin Chest Med. 2019; 40:561-572.

-Jouneau S, Hervier B, Jutant EM, Decaux O, Kambouchner M, Humbert M, Delaval P, Montani D. Les manifestations pulmonaires du syndrome des antisynthétases. Rev Mal Respir. 2015; 32:618-28.

-Concha JSS, Merola JF, Fiorentino D, Werth VP. Re-examining mechanic’s hands as a characteristic skin finding in dermatomyositis. J Am Acad Dermatol. 2018;78:769-775.

-Kurtzman DJB, Vleugels RA. Anti-melanoma differentiation-associated gene 5 (MDA5) dermatomyositis: A concise review with an emphasis on distinctive clinical features. J Am Acad Dermatol. 2018; 78:776-785.

-Sunderkötter C, Nast A, Worm M, Dengler R, Dörner T, Ganter H, Hohlfeld R, Melms A, Melzer N, Rösler K, Schmidt J, Sinnreich M, Walter MC, Wanschitz J, Wiendl H. Guidelines on dermatomyositis -excerpt from the interdisciplinary S2k guidelines on myositis syndromes by the German Society of Neurology. J Dtsch Dermatol Ges. 2016; 14:321-38.

-Moghadam-Kia S, Aggarwal R, Oddis CV. Myositis in clinical practice-relevance of new antibodies. Best Pract Res Clin Rheumatol. 2018; 32:887-901.

-Papadopoulou C, Wedderburn LR. Treatment of Juvenile Dermatomyositis: An Update. Paediatr Drugs. 2017; 19:423-43.

-Hughes M, Herrick AL. Systemic sclerosis. Br J Hosp Med (Lond). 2019; 80:530-536.

–Rubio-Rivas M, Moreno R, Corbella X. Occupational and environmental scleroderma. Systematic review and meta-analysis. Clin Rheumatol. 2017; 36:569-582.

-Lens XM, Fernandez E, Panades MJ, Casanova JM, Macia JM, Ramos J, Montolin J. Progressive systemic sclerosis and palmar hyperkeratosis as a paraneoplastic syndrome in non-Hodgkin’s lymphoma. Nephrol Dial Transplant. 1992; 7:1166-7.

-Varga J, Marangoni RG. Systemic sclerosis in 2016: Dermal white adipose tissue implicated in SSc pathogenesis. Nat Rev Rheumatol. 2017; 13:71-72.

-Yokoyama N, Kawasaki A, Matsushita T, Furukawa H, Kondo Y, Hirano F, Sada KE, Matsumoto I, Kusaoi M, Amano H, Nagaoka S, Setoguchi K, Nagai T, Shimada K, Sugii S, Hashimoto A, Matsui T, Okamoto A, Chiba N, Suematsu E, Ohno S, Katayama M, Migita K, Kono H, Hasegawa M, Kobayashi S, Yamada H, Nagasaka K, Sugihara T, Yamagata K, Ozaki S, Tamura N, Takasaki Y, Hashimoto H, Makino H, Arimura Y, Harigai M, Sato S, Sumida T, Tohma S, Takehara K, Tsuchiya N. Association of NCF1 polymorphism with systemic lupus erythematosus and systemic sclerosis but not with ANCA-associated vasculitis in a Japanese population. Sci Rep. 2019; 9:16366.

-Huang M, Cai G, Baugh LM, Liu Z, Smith A, Watson M, Popovich D, Zhang T, Stawski LS, Trojanowska M, Georgakoudi , Black LD 3rd, Pioli PA, Whitfield ML, Garlick J. Systemic Sclerosis Dermal Fibroblasts Induce Cutaneous Fibrosis Through LOXL4: New Evidence from 3D Skin-like Tissues. Arthritis Rheumatol. 2019. doi: 10.1002/art.41163.

-Freire M, Rivera A, Sopeña B, Tolosa Vilella C, Guillén-Del Castillo A, Colunga Argüelles D, Callejas Rubio JL, Rubio Rivas M, Trapiella Martínez L, Todolí Parra JA, Rodríguez Carballeira M, Iniesta Arandia N, García Hernández FJ, Egurbide Arberas MV, Sáez Comet L, Vargas Hitos JA, Ríos Blanco JJ, Marín Ballvé A, Pla Salas X, Madroñero Vuelta AB, Ruiz Muñoz M, Fonollosa Pla V, Simeón Aznar CP; RESCLE investigators, Autoimmune Diseases Study Group (GEAS). Clinical and epidemiological differences between men and women with systemic sclerosis: a study in a Spanish systemic sclerosis cohort and literature review. Clin Exp Rheumatol. 2017; 35 Suppl 106:89-97.

-Jaeger VK, Tikly M, Xu D, Siegert E, Hachulla E, Airò P, Valentini G, Matucci Cerinic M, Distler O, Cozzi F, Carreira P, Allanore Y, Müller-Ladner U, Ananieva LP, Balbir-Gurman A, Distler JHW, Czirják L, Li M, Henes J, Jimenez SA, Smith V, Damjanov N, Denton CP, DelGaldo F, Saketkoo LA, Walker UA; EUSTAR co-authors. Racial differences in systemic sclerosis disease presentation: a European Scleroderma Trials and Research group study. Rheumatology (Oxford). 2019. pii: kez486.

-Bielsa Marsol I. Update on the classification and treatment of localized scleroderma. Actas Dermosifiliogr. 2013; 104:654-66.

-Foeldvari I. Update on the Systemic Treatment of Pediatric Localized Scleroderma. Paediatr Drugs. 2019. doi: 10.1007/s40272-019-00363-5.

–Teske NM, Jacobe HT. Using the Localized Scleroderma Cutaneous Assessment Tool (LoSCAT) to classify morphoea by severity and identify clinically significant change. Br J Dermatol. 2019. doi: 10.1111/bjd.18097.

–Albuquerque JV, Andriolo BN, Vasconcellos MR, Civile VT, Lyddiatt A, Trevisani VF. Interventions for morphea. Cochrane Database Syst Rev. 2019; 7:CD005027.

-Mertens JS, Seyger MMB, Thurlings RM, Radstake TRDJ, de Jong EMGJ. Morphea and Eosinophilic Fasciitis: An Update. Am J Clin Dermatol. 2017; 18:491-512.

-Volkmann ER, Varga J. Emerging targets of disease-modifying therapy for systemic sclerosis. Nat Rev Rheumatol. 2019; 15:208-224.

–Sticherling M. Systemic sclerosis – the dermatological perspective. J Dtsch Dermatol Ges. 2019; 17:716-728.

–Schutyser W, Cruyt L, Vulsteke JB, Lenaerts JL, De Langhe E. The role of high-resolution manometry in the assessment of upper gastrointestinal involvement in systemic sclerosis: a systematic review. Clin Rheumatol. 2019. doi: 10.1007/s10067-019-04794-w.

–Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017; 390(10103):1685-1699.

-Schutyser W, Cruyt L, Vulsteke JB, Lenaerts JL, De Langhe E. The role of high-resolution manometry in the assessment of upper gastrointestinal involvement in systemic sclerosis: a systematic review. Clin Rheumatol. 2019. doi: 10.1007/s10067-019-04794-w.

–Kucharz EJ, Kopeć-Mędrek M. Systemic sclerosis sine scleroderma. Adv Clin Exp Med. 2017; 26:875-880).

-Nihtyanova SI, Sari A, Harvey JC, Leslie A, Derrett-Smith EC, Fonseca C, Ong VH, Denton CP. Using autoantibodies and cutaneous subset to develop outcome-based disease classification in systemic sclerosis. Arthritis Rheumatol. 2019. doi: 10.1002/art.41153.

-Devgire V, Hughes M. Raynaud’s phenomenon. Br J Hosp Med (Lond). 2019; 80:658-664.

-Torrens Cid LA, Soleto K CY, Montoro-Álvarez M, Sáenz Tenorio C, Silva-Riveiro A, López-Cerón A, Anzola Alfaro AM, Caballero Motta LR, Serrano Benavente B, Martínez-Barrio J, Ovalles-Bonilla JG, González Fernández CM, Monteagudo Sáez I, Nieto-González JC. Clinical Impact of Nailfold Capillaroscopy in Daily Clinical Practice. Reumatol Clin. 2019. pii: S1699-258X(19)30126-3.

-Alberti-Violetti S, Berti E, Marzano AV. Cutaneous and systemic vasculitides in dermatology: a histological perspective. G Ital Dermatol Venereol. 2018; 153:185-193.

–Sunderkötter CH, Zelger B, Chen KR, Requena L, Piette W, Carlson JA, Dutz J, Lamprecht P, Mahr A, Aberer E, Werth VP, Wetter DA, Kawana S, Luqmani R, Frances C, Jorizzo J, Watts JR, Metze D, Caproni M, Alpsoy E, Callen JP, Fiorentino D, Merkel PA, Falk RJ, Jennette JC. Nomenclature of Cutaneous Vasculitis: Dermatologic Addendum to the 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheumatol. 2018; 70:171-184.

–Mukherjee S, Era N, Mukherjee M, Tripathi SK. Leukocytoclastic vasculitis secondary to clozapine. Indian J Psychiatry. 2019; 61:94-96.

-Ekinci RMK, Balci S, Melek E, Karabay Bayazit A, Dogruel D, Altintas DU, Yilmaz M. Clinical manifestations and outcomes of 420 children with Henoch Schönlein Purpura from a single referral center from Turkey: A three-year experience. Mod Rheumatol. 2019: doi: 10.1080/14397595.2019.1687074.

–Yagi S, Endo I, Murakami T, Hida T, Yamamoto Y, Soga T, Ise T, Kusunose K, Yamaguchi K, Fukuda D, Yamada H, Soeki T, Wakatsuki T, Kawahito S, Sata M. Adult onset of Immunoglobulin A vasculitis -A case report. J Med Invest. 2019; 66:344-346.

-Mazzota M, Dotto B, Salazar V, Herrero M, Sesín AM, Dionisio de Cabalier ME, Mukdsi J. Crioglobulinemia mixta esencial tipo II: presentación de un caso. Rev Fac Cien Med Univ Nac Cordoba. 2018; 13;75:292-298. 

-Jachiet M, Flageul B, Bouaziz JD, Bagot M, Terrier B; Groupe Français d’Étude des Vascularites (GFEV). Les vascularites urticariennes hypocomplémentémiques. Rev Med Interne. 2018; 39:90-98

–Kolkhir P, Grakhova M, Bonnekoh H, Krause K, Maurer M. Treatment of urticarial vasculitis: A systematic review. J Allergy Clin Immunol. 2019; 143:458-466.

-Lally L, Spiera R. B-cell-targeted therapy in systemic vasculitis. Curr Opin Rheumatol. 2016; 28:15-20.

–Chasset F, Francès C. Cutaneous Manifestations of Medium- and Large-Vessel Vasculitis. Clin Rev Allergy Immunol. 2017; 53:452-468.

-Burns JC. The etiologies of Kawasaki disease. J Clin Invest. 2024; 134(5):e176938.

-Kuo HC. Diagnosis, Progress, and Treatment Update of Kawasaki Disease. Int J Mol Sci. 2023; 24(18):13948.

-Wang H, Shimizu C, Bainto E, Hamilton S, Jackson HR, Estrada-Rivadeneyra D, Kaforou M, Levin M, Pancheri JM, Dummer KB, Tremoulet AH, Burns JC. Subgroups of children with Kawasaki disease: a data-driven cluster analysis. Lancet Child Adolesc Health. 2023; 7(10):697-707.

-Rife E, Gedalia A. Kawasaki Disease: an Update. Curr Rheumatol Rep. 2020; 22(10):75.

-Alaygut D, Alparslan C, Öncel EP, Mutlubaş F, Özdemir T, Yavaşcan Ö, Kasap Demir B. A Child Diagnosed With Treatment-Resistant Polyarteritis Nodosa: Can the Clinical Diagnosis Be Different? Arch Rheumatol. 2019; 34:338-342.

–Kluger N, Pagnoux C, Guillevin L, Francès C; French Vasculitis Study Group. Comparison of cutaneous manifestations in systemic polyarteritis nodosa and microscopic polyangiitis. Br J Dermatol. 2008; 159:615-20.

–Forbess L, Bannykh S. Polyarteritis nodosa. Rheum Dis Clin North Am. 2015; 41:33-46.

-Morgan AJ, Schwartz RA. Cutaneous polyarteritis nodosa: a comprehensive review. Int J Dermatol. 2010; 49:750-6.

-Michailidou D, Rosenblum JS, Rimland CA, Marko J, Ahlman MA, Grayson PC. Clinical symptoms and associated vascular imaging findings in Takayasu’s arteritis compared to giant cell arteritis. Ann Rheum Dis. 2019. pii: annrheumdis-2019-216145.

-Águeda AF, Monti S, Luqmani RA, Buttgereit F, Cid M, Dasgupta B, Dejaco C, Mahr A, Ponte C, Salvarani C, Schmidt W, Hellmich B. Management of Takayasu arteritis: a systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis. RMD Open. 2019; 5:e001020.

-Dechant C, Schulze-Koops H. Update Riesenzellarteriitis. Dtsch Med Wochenschr. 2019; 144:1432-1436.

-Monti S, Águeda AF, Luqmani RA, Buttgereit F, Cid M, Dejaco C, Mahr A, Ponte C, Salvarani C, Schmidt W, Hellmich B. Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis. RMD Open. 2019; 5:e001003.